Skip to main content
Premium Trial:

Request an Annual Quote

Hitting the Big-Time

FDA has approved Novartis' Ilaris to treat a rare, genetic autoinflammatory disease, reports the Wall Street Journal. The paper's Health Blog adds that Ilaris is an example of that prized goal, personalized medicine. "It's also the first concrete result of Novartis's seven-year effort to target the genetic causes of disease. If it can find and fix the genetic switches that make people sick, Novartis believes, it will find truly effective drugs that patients need -- and that insurers are willing to pay for," the news article says. Novartis hopes that Ilaris will then act as an entry into more common genetic diseases.

The Scan

NFTs for Genome Sharing

Nature News writes that non-fungible tokens could be a way for people to profit from sharing genomic data.

Wastewater Warning System

Time magazine writes that cities and college campuses are monitoring sewage for SARS-CoV-2, an approach officials hope lasts beyond COVID-19.

Networks to Boost Surveillance

Scientific American writes that new organizations and networks aim to improve the ability of developing countries to conduct SARS-CoV-2 genomic surveillance.

Genome Biology Papers on Gastric Cancer Epimutations, BUTTERFLY, GUNC Tool

In Genome Biology this week: recurrent epigenetic mutations in gastric cancer, correction tool for unique molecular identifier-based assays, and more.